ArticleNature protocols2017
Directed differentiation and long-term maintenance of epicardial cells derived from human pluripotent stem cells under fully defined conditions.
Article in Nature protocols, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Cardiomyocyte vulnerability to lamin polymer disruption revealed by saturation mutagenesis.bioRxiv : the preprint server for biology · 2026Article
- Ginkgolide A enhances cardiomyocyte differentiation from pluripotent stem cells by targeting cytochrome c to attenuate intrinsic apoptosis.The Journal of biological chemistry · 2026Article
- Article
- Advances in Epicardial Biology: Insights from Development, Regeneration, and Human Cardiac Organoids.Journal of cardiovascular development and disease · 2025Review
- Developmental cues from epicardial cells simultaneously promote cardiomyocyte proliferation and electrochemical maturation.Stem cell reports · 2025Article
- Enhancing human pluripotent stem cell differentiation to cardiomyocytes through cardiac progenitor reseeding and cryopreservation.iScience · 2025Article
- Hypoimmunogenic hPSC-derived cardiac organoids for immune evasion and heart repair.bioRxiv : the preprint server for biology · 2025Article
- Customized Heparinized Alginate and Collagen Hydrogels for Tunable, Local Delivery of Angiogenic Proteins.ACS biomaterials science & engineering · 2025Article
- Exploring the Function of Epicardial Cells Beyond the Surface.Circulation research · 2024Review
- Subpopulations of fibroblasts derived from human iPS cells.Communications biology · 2024Article
- Engineered Cardiac Microtissue Biomanufacturing Using Human Induced Pluripotent Stem Cell Derived Epicardial Cells.bioRxiv : the preprint server for biology · 2024Article
- Decellularized heart extracellular matrix alleviates activation of hiPSC-derived cardiac fibroblasts.Bioactive materials · 2024Article
- The Neural Progenitor Cell-Associated Transcription Factor FoxG1 Regulates Cardiac Epicardial Cell Proliferation.Stem cells international · 2024Article
- Harnessing stem cell and lineage reprogramming technology to treat cardiac fibrosis.Cell regeneration (London, England) · 2023Review
- hESC-Derived Epicardial Cells Promote Repair of Infarcted Hearts in Mouse and Swine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Heart in a dish - choosing the right in vitro model.Disease models & mechanisms · 2023Article
- Retinoic acid signaling modulation guides in vitro specification of human heart field-specific progenitor pools.Nature communications · 2023Article
- Recapitulating porcine cardiac developmentFrontiers in cell and developmental biology · 2023Article
- Melanocyte stem cells in skin diseases and their potential in cell-based therapy.Histology and histopathology · 2022Review
- Challenges and opportunities for the next generation of cardiovascular tissue engineering.Nature methods · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Here, we describe how to efficiently direct human pluripotent stem cells (hPSCs) differentiation into self-renewing epicardial cells in a completely defined, xeno-free system by temporal modulation of regulators of canonical Wnt signaling. Appropriate differentiation-stage-specific application of Gsk3 inhibitor, Wnt inhibitor, and Gsk3 inhibitor (GiWiGi) is sufficient to produce cells expressing epicardial markers and exhibiting epicardial phenotypes with a high yield and purity from multiple hPSC lines in 16 d. Characterization of differentiated cells is performed via flow cytometry and immunostaining to assess quantitative expression and localization of epicardial cell-specific proteins. In vitro differentiation into fibroblasts and smooth muscle cells (SMCs) is also described. In addition, culture in the presence of transforming growth factor (TGF)-β inhibitors allows long-term expansion of hPSC-derived epicardial cells (for at least 25 population doublings). Functional human epicardial cells differentiated via this protocol may constitute a potential cell source for heart disease modeling, drug screening, and cell-based therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.